The Cancer MoonshotSM was designed to accelerate efforts to prevent, diagnose, and treat cancer and achieve 10 years of progress in 5 years. The associated Symptom Management Research Blue Ribbon Panel (BRP) identified the need for strategic investment in the collection of patient-reported symptom data and the use of that data to inform decision-making and improve clinical management. Specifically, the BRP noted that validated patient-reported measures (PROs) have led to advances in the systematic collection of patient-reported symptoms and functional status. However, these advances have not occurred uniformly across all populations, particularly among minority and underserved populations. Furthermore, these populations often have significant delays in treatment, experience worse side effects, are more likely to be nonadherent to treatment, and have less access to remedies to control their side effects. Consequently, they are at high risk for impaired quality of life, functionality, working, and family relationships. Within this population of minority and underserved can be found a growing number of non-English or low-English proficient speaking individuals. While the Panel noted that systematically gathered PRO data from underserved populations are needed, without adequate and appropriate translations of PRO questionnaires, non-English and low-English proficient patients will remain marginalized, undertreated, and underrepresented in clinical trials. While most of general quality of life questionnaires and the Patient Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE) are translated in multiple languages, some gaps remain. In addition, protocols often include ancillary non-validated materials (e.g., patient diaries,instructions) that are typically only available in English. Finally, neurocognitive tests are frequently used in both adult and pediatric trials and the lack of translations limits participation of non-English speakers. Thus, this Moonshot effort is intended to improve accrual of Spanish and French speakers to the NCORP clinical trial portfolio by ensuring the availability of the necessary translated materials. The NCI Community Oncology Research Program (NCORP) is a national NCI-supported network that designs and conducts cancer prevention, supportive care and symptom management, screening, and surveillance clinical trials. The NCORP is housed in the NCI Division of Cancer Prevention and collaborates with numerous other NCI Divisions and Offices. NCORP is comprised of 7 Research Bases and 46 Community Sites, 14 of which are designated as Minority/Underserved Community Sites. The NCORP Research Bases are hubs for the network that design and spearhead the conduct of multi-center clinical trials and provide overall administration, data management, scientific and statistical leadership, operational processes and personnel, and regulatory compliance. The NCORP Community Sites accrue participants to NCI-approved ca...